DNA Biomed (Israel) Probability of Future Stock Price Finishing Over 23.71

DNA Stock  ILS 76.90  0.20  0.26%   
DNA Biomed's future price is the expected price of DNA Biomed instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of DNA Biomed Solns performance during a given time horizon utilizing its historical volatility. Check out DNA Biomed Backtesting, DNA Biomed Valuation, DNA Biomed Correlation, DNA Biomed Hype Analysis, DNA Biomed Volatility, DNA Biomed History as well as DNA Biomed Performance.
  
Please specify DNA Biomed's target price for which you would like DNA Biomed odds to be computed.

DNA Biomed Target Price Odds to finish over 23.71

The tendency of DNA Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above S 23.71  in 90 days
 76.90 90 days 23.71 
close to 99
Based on a normal probability distribution, the odds of DNA Biomed to stay above S 23.71  in 90 days from now is close to 99 (This DNA Biomed Solns probability density function shows the probability of DNA Stock to fall within a particular range of prices over 90 days) . Probability of DNA Biomed Solns price to stay between S 23.71  and its current price of S76.9 at the end of the 90-day period is about 81.42 .
Assuming the 90 days trading horizon the stock has the beta coefficient of 1.3 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, DNA Biomed will likely underperform. Additionally DNA Biomed Solns has an alpha of 0.1961, implying that it can generate a 0.2 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
   DNA Biomed Price Density   
       Price  

Predictive Modules for DNA Biomed

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as DNA Biomed Solns. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of DNA Biomed's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
73.7376.9080.07
Details
Intrinsic
Valuation
LowRealHigh
71.5874.7577.92
Details
Naive
Forecast
LowNextHigh
67.7370.9174.08
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
76.6476.8377.02
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as DNA Biomed. Your research has to be compared to or analyzed against DNA Biomed's peers to derive any actionable benefits. When done correctly, DNA Biomed's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in DNA Biomed Solns.

DNA Biomed Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. DNA Biomed is not an exception. The market had few large corrections towards the DNA Biomed's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold DNA Biomed Solns, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of DNA Biomed within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
0.20
β
Beta against NYSE Composite1.30
σ
Overall volatility
6.55
Ir
Information ratio 0.07

DNA Biomed Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of DNA Biomed for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for DNA Biomed Solns can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
DNA Biomed Solns had very high historical volatility over the last 90 days
The company has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist DNA Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, DNA Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DNA Biomed Solns sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DNA to invest in growth at high rates of return. When we think about DNA Biomed's use of debt, we should always consider it together with cash and equity.
DNA Biomed Solns has accumulated about 492 K in cash with (2.33 M) of positive cash flow from operations.
Roughly 55.0% of the company shares are held by company insiders

DNA Biomed Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of DNA Stock often depends not only on the future outlook of the current and potential DNA Biomed's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. DNA Biomed's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding99.7 M

DNA Biomed Technical Analysis

DNA Biomed's future price can be derived by breaking down and analyzing its technical indicators over time. DNA Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of DNA Biomed Solns. In general, you should focus on analyzing DNA Stock price patterns and their correlations with different microeconomic environments and drivers.

DNA Biomed Predictive Forecast Models

DNA Biomed's time-series forecasting models is one of many DNA Biomed's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary DNA Biomed's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about DNA Biomed Solns

Checking the ongoing alerts about DNA Biomed for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for DNA Biomed Solns help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
DNA Biomed Solns had very high historical volatility over the last 90 days
The company has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist DNA Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, DNA Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DNA Biomed Solns sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DNA to invest in growth at high rates of return. When we think about DNA Biomed's use of debt, we should always consider it together with cash and equity.
DNA Biomed Solns has accumulated about 492 K in cash with (2.33 M) of positive cash flow from operations.
Roughly 55.0% of the company shares are held by company insiders
Check out DNA Biomed Backtesting, DNA Biomed Valuation, DNA Biomed Correlation, DNA Biomed Hype Analysis, DNA Biomed Volatility, DNA Biomed History as well as DNA Biomed Performance.
Note that the DNA Biomed Solns information on this page should be used as a complementary analysis to other DNA Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for DNA Stock analysis

When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Please note, there is a significant difference between DNA Biomed's value and its price as these two are different measures arrived at by different means. Investors typically determine if DNA Biomed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DNA Biomed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.